T-cell receptor-Cluster of differentiation 3 complex (TCR-CD3)

The T-cell receptor-Cluster of differentiation 3 (TCR-CD3) complex is a multi-subunit transmembrane protein assembly found on the surface of T lymphocytes, including Cytokine-Induced Killer (CIK) cells (PMID: 1830400). CIK cells are a unique population of immune effector cells, primarily CD3+CD56+ NKT-like cells, generated through the ex vivo stimulation of peripheral blood mononuclear cells with interferon-gamma, interleukin-2, and anti-CD3 antibodies like Muromonab-CD3 (PMID: 25893421). Within this context, the TCR-CD3 complex serves as a critical target for the initial activation and expansion of CIK cells during the manufacturing process (UniProt: P07766). Furthermore, the complex is targeted by bispecific antibodies to redirect CIK cell cytotoxicity toward specific tumor-associated antigens, bypassing MHC restriction in some contexts (PMID: 24652987). Therapeutically, modulating this complex is essential for adoptive cell therapies in oncology, though it carries risks such as cytokine release syndrome due to potent immune activation (NIH: StatPearls - Cytokine Release Syndrome).

Other names

CD3 complexTCR-CD3 complexT-cell receptor complexCD3 antigenT3 complexT-cell receptor-CD3 complex

The TCR-CD3 complex is targeted by monoclonal antibodies to induce T-cell activation and expansion for adoptive cell therapy, or by bispecific T-cell engagers (BiTEs) to bridge T cells with tumor cells, triggering MHC-independent cytotoxicity. In autoimmune contexts, anti-CD3 antibodies may induce T-cell depletion or TCR internalization to achieve immunosuppression.